Treatment Registry
TR-0752 ActiveRecorded September 2026Last verified October 2026

Compounded tirzepatide

Sold by Actin · Injection · device not recorded · every compounded tirzepatide record

The program identifies an injection, but the delivery device has not been established.

Price

TermPublished rateCharged today
Standard tirzepatide — 1-month selection, advertised $269; payment interval unverified

Price conditions have not been established; the quoted figure is not a verified recurring rate.

Prescription and individual/state eligibility required. This is an advertised figure, not a verified charge today or recurring invoice; plan labels and delivery descriptions do not establish a calendar-month payment interval.

Advertised

“Most Flexible 1-Month $269”

$269Published figureCharged todayNot verified
Standard tirzepatide — 3-month selection, advertised $209; payment interval unverified

Price conditions have not been established; the quoted figure is not a verified recurring rate.

Prescription and individual/state eligibility required. This is an advertised figure, not a verified charge today or recurring invoice; plan labels and delivery descriptions do not establish a calendar-month payment interval.

Advertised

“Most Popular 3-Month $209”

$209Published figureCharged todayNot verified
Standard tirzepatide — 6-month selection, advertised $166; payment interval unverified

Price conditions have not been established; the quoted figure is not a verified recurring rate.

Prescription and individual/state eligibility required. This is an advertised figure, not a verified charge today or recurring invoice; plan labels and delivery descriptions do not establish a calendar-month payment interval.

Advertised

“Best Value 6-Month $166”

$166Published figureCharged todayNot verified
Price sources
Visit Actin

We earn nothing from this link. It opens Actin's website without a paid referral.

History

Fewer than two comparable calendar-month readings are available for a price trend. Day- or week-based supplies, introductory offers and unverified payment terms are not connected in this chart.

  • September 2026 — Entry added to the register

Sourcing and terms

PharmacyNot disclosed
StatesNot disclosed
PrescriberNot disclosed
CancellationSubscriptions may renew automatically at checkout-defined intervals. Cancellation through the account or support takes effect after the current subscription period. The terms describe sales and subscription fees as final/nonrefundable while reserving case-by-case remedies.
MembershipNone. “No hidden fees or membership required”
Consult feeNot disclosed

Recorded from actin.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.

Notes

  1. 1. September 2026 — Homepage badge literally reads 'No Membership Fees' and both product pages say 'Same price, forever' and 'No hidden fees or membership required' — the per-month figures already include the medication, this is not the membership trap. Per-month prices for the 3/6-month plans are the only figures printed; no separate upfront total was shown, so upfront was recorded equal to perMonth rather than computed. Device form (vial vs. pen) is never stated for either drug.
  2. 2. October 2026 — Actin Telehealth, Inc. operates the platform and says it is not a healthcare provider. The public footer names Beluga Health, P.A. for medical services; no individual treating clinician or independent credential verification is established. Source: https://actin.com/page/terms-of-service.
  3. 3. October 2026 — The public footer lists The Pharmacy Hub, GreenwichRX and Hallandale Pharmacy. This is a disclosed partner network, not confirmation of the pharmacy assigned to this program. Product pictures are explicitly illustrative. Source: https://actin.com/.
  4. 4. October 2026 — No membership fee is advertised. The products include clinician support, dose adjustments, wipes, syringes and delivery. The terms describe a single subscription total that can include provider and pharmacy charges; no separate universally required consultation amount is established in the reviewed public pages. Source: https://actin.com/lose-weight/compounded-semaglutide.
  5. 5. October 2026 — The terms describe cash-pay services and say the practices do not accept commercial health insurance or Medicare/Medicaid. HSA/FSA and financing badges do not establish insurance coverage. Source: https://actin.com/page/terms-of-service.
  6. 6. October 2026 — Services are limited to eligible U.S. locations, and some services are available only in certain states. The reviewed public pages do not establish a complete treatment-specific state roster. No current lab requirement or included lab price is established. Source: https://actin.com/page/terms-of-service.
  7. 7. October 2026 — The public process describes clinician review of submitted information and continuing in-app messaging. A mandatory live-visit requirement is not established on the reviewed pages. The linked support FAQ returned a security-verification page and was not bypassed. Source: https://actin.com/.
  8. 8. October 2026 — Subscriptions can renew automatically at intervals described during checkout. Cancellation through the account or support takes effect after the current subscription period. The terms describe sales and subscription fees as final/nonrefundable, while reserving case-by-case remedies. Confirm the final invoice and renewal terms before purchase. Source: https://actin.com/page/terms-of-service.
  9. 9. October 2026 — Product pages advertise free delivery, and the terms say delivery estimates are not guaranteed and any applicable shipping charges appear before purchase. The actual order total and renewal charge remain unverified. Source: https://actin.com/page/terms-of-service.
  10. 10. October 2026 — The general GLP-1 landing page repeats the semaglutide and tirzepatide starting figures and advertises $50 off a first order. The offer does not establish which plan qualifies or a discounted recurring price, so no subtraction or extra ingredient record is inferred. Source: https://actin.com/lose-weight/compounded-glp1.
  11. 11. October 2026 — The Key Info tab describes tirzepatide personalized with B12 or glycine. The public text does not establish one universal additive formulation or dispensing device for every patient. Source: https://actin.com/lose-weight/compounded-tirzepatide.

1 further note concerns other Actin programs and sit on the provider record.

Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.

This record

Entry
TR-0752
Medication category
compounded tirzepatide
Readings
2

Related records

Cite this entry

Treatment Registry. (2026). Actin — compounded tirzepatide (TR-0752). Last verified October 2026. Retrieved [your access date], from https://treatmentregistry.com/registry/TR-0752

Replace the bracket with the date you read it. Ours is the date we last checked the figures, which is a different thing and is given separately.